SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 2,738.06 |
| Enterprise Value ($M) | 2,343.47 |
| Book Value ($M) | 485.38 |
| Book Value / Share | 9.11 |
| Price / Book | 5.64 |
| NCAV ($M) | 376.61 |
| NCAV / Share | 7.07 |
| Price / NCAV | 7.27 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.12 |
| Return on Assets (ROA) | -0.11 |
| Return on Equity (ROE) | -0.23 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.06 |
| Current Ratio | 6.06 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 716.36 |
| Assets | 825.13 |
| Liabilities | 339.75 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 110.32 |
| Operating Income | -89.88 |
| Net Income | -70.69 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 207.57 |
| Cash from Investing | -154.51 |
| Cash from Financing | 279.16 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Fmr Llc | 10.22 | 23.19 | |
| 13D/A | Sr One Capital Management, Llc | 4.44 | -25.42 | |
| 13G/A | Paradigm Biocapital Advisors LP | 7.00 | 51.01 | |
| 13G/A | Perceptive Advisors Llc | 8.80 | 74.91 | |
| 13G/A | Suvretta Capital Management, Llc | 5.00 | 3.64 | |
| 13G | BlackRock Inc. | 6.20 | 40.00 | |
| 13G/A | Gilead Sciences Inc | 12.90 | 93.22 | |
| 13D/A | New Enterprise Associates 15, L.P. | 7.80 | -21.09 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No. 1 | ||
| Form 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 49,804 | 122,054 | 40.80 | |
| 80,766 | 159,320 | 50.69 | |
| 46,883 | 150,977 | 31.05 | |
| 88,173 | 152,752 | 57.72 | |
| 97,812 | 169,275 | 57.78 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABOS – Acumen Pharmaceuticals, Inc. | ABUS – Arbutus Biopharma Corporation |
| ACAD – ACADIA Pharmaceuticals Inc. | ACRS – Aclaris Therapeutics, Inc. |
| ACT – Enact Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io